Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma
Authors
Keywords
-
Journal
Cancer Biomarkers
Volume -, Issue -, Pages 1-11
Publisher
IOS Press
Online
2023-09-15
DOI
10.3233/cbm-230159
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hallmarks of Cancer: New Dimensions
- (2022) Douglas Hanahan Cancer Discovery
- Immunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy
- (2022) Joshua Hofbauer et al. Biomolecules
- Site-specific Response to Nivolumab in Renal Cell Carcinoma
- (2021) TAKAHITO NEGISHI et al. ANTICANCER RESEARCH
- Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
- (2021) Jacqueline T Brown et al. Journal for ImmunoTherapy of Cancer
- Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab
- (2020) A. Simonaggio et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
- (2019) Akinori Sasaki et al. Gastric Cancer
- Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
- (2019) Zhibo Zhang et al. Cancer Medicine
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
- (2019) Mehmet Asim Bilen et al. BMC CANCER
- Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
- (2018) Junko Tanizaki et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
- (2018) Motohiro Tamiya et al. PLoS One
- Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
- (2018) Samuel Rosner et al. Cancer Medicine
- The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
- (2018) Nick van Dijk et al. EUROPEAN UROLOGY
- Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab
- (2018) Hisako Okuhira et al. BioScience Trends
- The immune system in cancer metastasis: friend or foe?
- (2017) Louise M.E. Janssen et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
- (2016) Yoshio Nakamura et al. Oncotarget
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) Arnoud J. Templeton et al. JNCI-Journal of the National Cancer Institute
- Tumor associated macrophages and neutrophils in cancer
- (2013) Maria Rosaria Galdiero et al. IMMUNOBIOLOGY
- Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients WithKRASWild-Type Unresectable Colorectal Liver-Limited Metastases
- (2013) Le-Chi Ye et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center
- (2011) Ignacio Garrido-Laguna et al. CANCER
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
- (2008) H-T Arkenau et al. BRITISH JOURNAL OF CANCER
- Prognostic Impact of Postoperative C-Reactive Protein Level in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy
- (2008) Manabu Tatokoro et al. JOURNAL OF UROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now